scispace - formally typeset
Search or ask a question
Institution

Purdue Pharma

CompanyPickering, Ontario, Canada
About: Purdue Pharma is a company organization based out in Pickering, Ontario, Canada. It is known for research contribution in the topics: Buprenorphine & Chronic pain. The organization has 622 authors who have published 691 publications receiving 31545 citations. The organization is also known as: Purdue Pharmaceuticals L.P..


Papers
More filters
Journal ArticleDOI
TL;DR: Investigation using deuterium-labeled oxycodone and analysis by LC/MS showed that gem diol and hemiketal adducts of oxy codone formed as a result of the equilibrium addition of water and methanol to the C-6 ketone on oxycod one.

24 citations

Patent
27 Nov 1995
TL;DR: In this article, the authors measured the dissolution rate in-vitro of the dosage form, when measured by the USP Paddle Method of 100 rpm in 900 ml aqueous buffer at 37° C.
Abstract: Solid controlled-release oral dosage forms comprising a therapeutically effective amount of an opioid analgesic or a salt thereof which provide an extended duration of pain relief of about 24 hours, have a dissolution rate in-vitro of the dosage form, when measured by the USP Paddle Method of 100 rpm in 900 ml aqueous buffer at 37° C. from about 12.5% to about 42.5% (by weight) active agent released after 1 hour, from about 25% to about 55% (by weight) active agent released after 2 hours, from about 45% to about 75% (by weight) opioid analgesic released after 4 hours and greater than about 60% (by weight) opioid analgesic released after 8 hours, the in-vitro release rate being substantially independent of pH and chosen such that the peak plasma level of active agent obtained in-vivo between about 2 and about 8 hours after administration of the dosage form.

24 citations

Patent
Huang Haiyong Hugh1
22 Mar 2012
TL;DR: In this article, a tamper resistant dosage form comprising a first layer comprising an active agent and a second layer not comprising said active agent, and processes of manufacture, uses, and methods of treatment thereof providing essentially zero order release is described.
Abstract: The present invention relates to pharmaceutical multilayer dosage forms, for example to a tamper resistant dosage form comprising a first layer comprising an active agent and a second layer not comprising said active agent, and processes of manufacture, uses, and methods of treatment thereof providing essentially zero order release

24 citations

Journal ArticleDOI
TL;DR: It is concluded that SEP gradients in smoking emerge across birth cohorts rather than time alone, with increasingly strong gradients across time especially among younger cohorts.

24 citations

Journal ArticleDOI
TL;DR: The replication analysis found an upward trend in the prevalence of diagnosed opioids abuse over time and substantial excess annual per patient health care costs of diagnosed opioid abuse among commercially insured individuals, suggesting that these findings are generalizable to other commercially insured populations.
Abstract: The abuse of prescription opioids imposes a substantial public health and economic burden. Recent research using administrative claims data has substantiated the prevalence and cost of opioid abuse among commercially insured individuals. Although administrative claims data are readily available and have been used to effectively answer research questions about the burden of illness for many different conditions, an important issue is the reliability, replicability, and generalizability of estimates derived from different databases. Therefore, this study sought to assess whether the findings of a recently published study of opioid abuse in a commercial claims database (original analysis) could be replicated in a different commercial claims database. The original analysis, which analyzed the prevalence and excess health care costs of diagnosed opioid abuse in the OptumHealth Reporting and Insights Database, was replicated by applying the same approach to the Truven MarketScan Commercial Claims and En...

24 citations


Authors

Showing all 622 results

Network Information
Related Institutions (5)
Eli Lilly and Company
22.8K papers, 946.7K citations

87% related

Pfizer
37.4K papers, 1.6M citations

86% related

AstraZeneca
23.4K papers, 938.2K citations

84% related

GlaxoSmithKline
21.1K papers, 1.1M citations

83% related

Novartis
50.5K papers, 1.9M citations

83% related

Performance
Metrics
No. of papers from the Institution in previous years
YearPapers
20218
202013
201915
201819
201750
201640